IP Library Granted Patent US 8,563,613
Granted Patent B2
US 8,563,613 · App. 13/564,688 · Granted Oct 22, 2013

Diclofenac topical formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,613
App. No.
13/564,688
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.

Claims (46)

1. A topical formulation comprising:

(i) 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, or 5.0% w/w and all fractions in between, diclofenac sodium;

(ii) 30-60% w/w DMSO;

(iii) 1-15% w/w propylene glycol;

(iv) 1-30% w/w ethanol;

(v) optionally glycerine;

(vi) water;

(vii) at least one thickening agent selected from the group consisting of a

cellulose polymer, a carbomer polymer, a carbomer derivative, a cellulose derivative, and mixtures thereof; wherein the topical formulation has a viscosity of 500-5000 centipoise; and wherein the formulation degrades by less than 1% over 6 months.

2. The topical formulation of claim 1 , wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1%, 1.5% and 2% w/w, and all fractions in between.

3. The topical formulation of claim 1 , wherein the concentration of DMSO is about 40% to about 50% w/w.

4. The topical formulation of claim 3 , wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

5. The topical formulation of claim 1 , wherein the concentration of ethanol is present at 23-29% w/w.

6. The topical formulation of claim 1 , wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof.

7. The topical formulation of claim 6 , wherein the at least one thickening agent is selected from the group consisting of carbopol 971, carbopol 981, carbopol 941, carbopol 1342 and ultrez 10.

8. The topical formulation of claim 6 , wherein glycerine is present.

9. The topical formulation of claim 1 , wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof.

10. The topical formulation of claim 9 , wherein the at least one thickening agent is hydroxypropyl cellulose.

11. The topical formulation of claim 10 , wherein the formulation comprises:

(i) 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 or 5.0% w/w, and all fractions in between, of diclofenac sodium;

(ii) 40-50% w/w of DMSO;

(iii) 23-29% w/w of ethanol; and

(iv) 10-12% w/w of propylene glycol.

12. The topical formulation of claim 11 , wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1.5% and 2% w/w, and all fractions in between.

13. The topical formulation of claim 11 , wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

14. The topical formulation of claim 11 , wherein the concentration of ethanol is present at 26.5% w/w.

15. A method for treating pain in a subject suffering from pain, said method comprising the topical administration of a formulation comprising:

(i) diclofenac sodium present at 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, or 5.0% w/w and all fractions in between;

(ii) DMSO present at 30-60% w/w;

(iii) ethanol present at 1-30% w/w;

(iv) propylene glycol present at 1-15% w/w;

(v) optionally glycerine;

(vi) a thickening agent, wherein said thickening agent is selected from the group consisting of cellulose polymers, carbomer polymers, a carbomer derivative, a cellulose derivative and mixtures thereof; and

(vii) water; wherein the formulation has a viscosity of 500-5000 centipoise; and

wherein the formulation degrades by less than 1% over 6 months.

16. The method of claim 15 , wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1%, 1.5% and 2% w/w, and all fractions in between.

17. The method of claim 15 , wherein the concentration of DMSO is about 40% to about 50% w/w.

18. The method of claim 17 , wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

19. The method of claim 15 , wherein the concentration of ethanol is present at 23-29% w/w.

20. The method of claim 15 , wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof.

21. The method of claim 20 , wherein glycerine is present.

22. The method of claim 15 , wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof.

23. The method of claim 22 , wherein the at least one thickening agent is hydroxypropyl cellulose.

24. The formulation of claim 1 , wherein the formulation degrades by less than 0.5% over 6 months.

25. The formulation of claim 1 , wherein the formulation degrades by less than 0.2% over 6 months.

26. The formulation of claim 1 , wherein the formulation degrades by less than 1% over 6 months at room temperature.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS IRELAND DAC (SUCCESSOR IN INTEREST TO HORIZON PHARMA SERVICES LIMITED); HORIZON THERAPEUTICS IRELAND DAC (FKA HORIZON PHARMA IRELAND LIMITED); HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED
Reel/Frame 065153/0953 →
CHANGE OF NAME Recorded Oct 27, 2022
From: HZNP MEDICINES LLC
To: HZNP FINANCE LIMITED
Reel/Frame 061562/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2022
From: HZNP FINANCE LIMITED
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 061563/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: HZNP LIMITED
To: HZNP MEDICINES LLC
Reel/Frame 046455/0582 →
SECURITY INTEREST Recorded May 7, 2015
From: HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 035591/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2014
From: NUVO RESEARCH INC.
To: HZNP LIMITED
Reel/Frame 034068/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: KISAK, ED; SINGH, JAGAT
To: NUVO RESEARCH INC.
Reel/Frame 030823/0900 →